Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations

Vaccine

Volumn 15, Issue 9, 1997, Pages 1001-1007

  Newman, M J ^a,c   Wu, J Y ^a   Gardner, B H ^a   Anderson, C A ^a   Kensil, C R ^a   Recchia, J ^a   Coughlin, R T ^a   Powell, M F ^b  

^a Aquila Biopharmaceuticals Inc   (United States)

^b GENENTECH INC   (United States)

^c Vaxcel Inc   (United States)

Author keywords

Cytotoxic T lymphocyte (CTL); Glycoprotein 120 (pg120); Human immunodeficiency virus type 1 (HIV 1); QS 21; Saponin adjuvant; Subunit vaccine

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; QS 21; RECOMBINANT PROTEIN; SAPONIN; SYNTHETIC PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY SPECIFICITY; CHO CELLS; CRICETINAE; CROSS REACTIONS; EPITOPES, T-LYMPHOCYTE; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNODOMINANT EPITOPES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; SAPONINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC;

EID: 0031171898     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(96)00293-9     Document Type: Article

References (46)

1. 1 Gotch, F.M., Nixon, D.F., Alp, N., McMichael, A.J. and Borysiewicz, L.K. High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropositive individuals. Int. Immunol. 1990, 2, 707-712
2. 2 Hoffenbach, A., Langlade-Demoyen, P. and Dadaglio, G. et al. Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J. Immunol. 1989, 142, 452-462
3. 3 Walker, B.D., Chakrabarti, S. and Moss, B. et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987, 328, 345-348
4. 4 Walker, B.D., Flexner, C. and Paradis, T.J. et al. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science 1988, 240, 64-66
5. 5 Koenig, S., Earl, P. and Powell, D. et al. Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual. Proc. Natl Acad. Sci. USA 1988, 85, 8638-8642
6. 6 Brinchmann, J.E., Gaudernack, G. and Vartdal, F. CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. J. Immunol. 1990, 144, 2961-2966
7. 7 Kannagi, M., Masuda, T. and Hattori, T. et al. Interference with human immunodeficiency virus (HIV) replication by CD8+ T cells in peripheral blood leukocytes of asymptomatic HIV carriers in vitro. J. Virol. 1990, 64, 3399-3406
8. 8 Walker, C.M., Moody, D.J., Stites, D.P. and Levy, J.A. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986, 234, 1563-1566
9. 9 Mackewicz, C. and Levy, J.A. CDS+ cell anti-HIV activity: nonlytic suppression of virus replication. AIDS. Res. Hum. Retroviruses 1992, 6, 1039-1050
10. + T cells. Science 1995, 270, 1811-1815
11. 11 Plata, F. Implications of HIV-specific cytotoxic T lymphocytes in AIDS. Biotherapy 1992, 5, 31-45
12. 12 Koup, R.A., Safrit, J.T. and Cao, Y. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 1994, 68, 4650-4655
13. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 1994, 68, 6103-6110
14. 14 Takahashi, H., Cohen, J. and Hosmalin, A. et al. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatability complex molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl Acad. Sci. USA 1988, 85, 3105-3109
15. 15 Takahashi, H., Germain, R.N., Moss, B. and Berzofsky, J.A. An immunodominant clas I restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 class II restricted help for itself. J. Exp. Med. 1990, 171, 571-576
16. 16 Takahashi, H., Nakagawa, Y. and Pendleton, C.D. er al. Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant. Science 1992, 255, 333-336
17. 17 Takahashi, H., Merli, S. and Putney, S.D. et al. A single amino acid interchange yields reciprocal CTL specificities for HIV 1 gp160. Science 1989, 246, 118-121
18. 18 Chada, S., DeJesus, C.E. and Townsend, K. et al. Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytes. J. Virol. 1993, 67, 3409-3417
19. 19 Johnson, R.P., Trocha, A., Buchanan, T.M. and Walker, B.D. Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation. J. Exp. Med. 1992, 175, 961-971
20. 20 Johnson, R.P., Hammond, S.A., Trocha, A., Siliciano, R.F. and Walker, B.D. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine. J. Virol. 1994, 68, 3145-3153
21. 21 Safrit, J.T., Andrews, C.A., Zhu, T., Ho, D.D. and Koup, R.A. Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: recognition of autologous virus sequences within a conserved immunodominant epitope. J. Exp. Med. 1994, 179, 463-472
22. 22 Johnson, R.P., Trocha, A., Buchanan, T.M. and Walker, B.D. Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone. J. Virol. 1993, 67, 438-445
23. 23 Johnson, R.P. and Walker, B.D. Cytotoxic T lymphocytes in human immunodeficiency virus infection: responses to structural proteins. Curr. Top. Microbiol. Immunol. 1994, 189, 35-63
24. + cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J. Exp. Med. 1992, 176, 1531-1542
25. 25 Cooney, E.L., McElrath, M.J. and Corey, L. et al. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc. Natl Acad. Sci. USA 1993, 90, 1882-1886
26. + cytotoxic activity after receipt of envelope vaccines. J. Infect. Dis. 1993, 168, 306-313
27. 27 Johnson, R.P., Hammond, S.A., Trocha, A., Siliciano, R.F. and Walker, B.D. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine. AIDS. Res. Hum. Retroviruses 1994, 10 Suppl. 2, S73-S75
28. B peptide in an HLA-A11-immunized individual. AIDS. Res. Hum. Retroviruses 1994, 10, 19-26
29. MN. J. Infect. Dis. 1994, 169, 274-280
30. 30 Takahashi, H., Takeshita, T., Morein, B., Putney, S., Germain, R.N. and Berzofsky, J.A. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 1990, 344, 873-875
31. + cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. Proc. Natl Acad. Sci. USA 1991, 88, 9448-9452
32. 32 Wu, J.-Y., Gardner, B.H. and Murphy, C.I. et al. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J. Immunol. 1992, 148, 1519-1525
33. 33 Berman, P.W., Riddle, L. and Nakamura, G. et al. Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160. J. Virol. 1989, 63, 3489-3498
34. 34 Berman, P.W., Matthews, T.J. and Riddle, L. et al. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J. Virol. 1992, 66, 4464-4469
35. 35 Kensil, C.R., Patel, U., Lennick, M. and Marciani, D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria molina cortex. J. Immunol. 1991, 146, 431437
36. 36 Nakano, J.H. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections. American Public Health Association, Washington, DC, 1979, p. 257
37. 37 Berzofsky, J.A., Pendleton, C.D. and Clerici, M. et al. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitroT cell responses in mice and humans of multiple MHC types. J. Clin. Invest. 1991, 88, 876-884
38. 38 Clerici, M., Lucey, D.R., Zajac, R.A. et al. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J. Immunol. 1991, 146, 2214-2219
39. 39 Clerici, M., Stocks, N.I., Zajac, R.A. et al. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature 1989, 339, 383-385
40. 40 Hale, P.M., Cease, K.B. and Houghten, R.A. et al. T cell multideterminant regions in the human immunodeficiency virus envelope: toward overcoming the problem of major histocompatibility complex restriction. Int. Immunol. 1989, 1, 409-415
41. 41 Eriksson, K., Horal, P. and Svennerholm, B. et al. Systematic identification of T-cell activating epitopes on the human immunodeficiency virus type 1 envelope glycoprotein gp120 in primates immunized with synthetic peptides. Vaccine 1993, 11, 859-665
42. 42 Barany, G. and Merrifield, R.B. The Peptides - 2. Academic Press, New York, 1980
43. 43 Munroe, K.J., Anderson, C.A., Wu, J.-Y., Wyand, M.S., Newman, G.W. and Newman, M.J. Use of fixed autologous stimulator cells to correctly present human immunodeficiency virus type 1 peptides to nonhuman primate lymphocytes in Proliferation and cytotoxic T-lymphocyte assays. Clin. Diagnost. Lab. Immunol. 1994, 1, 283-289
44. 44 Gartner, S. and Popovic, M. Virus isolation and production. In: Techniques in HIV Research (Eds Aldovini, A. and Walker, B.D.). Stockton Press, New York, 1990, pp. 53-70
45. mac251 gag and env vaccines containing QS-21 saponin adjuvant. AIDS. Res. Hum. Retroviruses 1994, 10, 853-861
46. 46 Warner, J.F., Anderson, C.-G. and Laube, L. et al. Induction of HIV-specific CTL and antibody responses in mice using retroviral vector-transduced cells. AIDS. Res. Hum. Retroviruses 1991, 7, 645-655